History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Albina N. Minlikeeva(Roswell Park Comprehensive Cancer Center), Jolanta Kupryjańczyk(Cedars-Sinai Medical Center), Elisa V. Bandera(Rutgers, The State University of New Jersey), Kunle Odunsi(University of Chicago), Ellen L. Goode(Mayo Clinic in Arizona), Helen Steed(University of Alberta), Peter A. Fasching(Universitätsklinikum Erlangen), Jenny Chang‐Claude(Universität Hamburg), Linda E. Kelemen(Medical University of South Carolina), Anna DeFazio(The University of Sydney), Thilo Dörk(Hannover Re (Germany)), Paul Mayor(Roswell Park Comprehensive Cancer Center), Estrid Høgdall(University of Copenhagen), J. Brian Szender(Roswell Park Comprehensive Cancer Center), Rikki Cannioto(Roswell Park Comprehensive Cancer Center), Susanne K. Kjær(Copenhagen University Hospital), Marc T. Goodman(Cedars-Sinai Medical Center), Matthias W. Beckmann(Universitätsklinikum Erlangen), Leon F.A.G. Massuger(Radboud University Nijmegen), Lambertus A. Kiemeney(Radboud University Nijmegen), Simon A. Gayther(The University of Texas Health Science Center at Houston), Aleksandra Gentry‐Maharaj(UCL Australia), Susan J. Ramus(Cancer Institute of New South Wales), Kathryn L. Terry(Brigham and Women's Hospital), Emese Zsíros, Brahm H. Segal(Roswell Park Comprehensive Cancer Center), Daniel W. Cramer(Brigham and Women's Hospital), Grace Friel(Kaleida Health), Jo L. Freudenheim(University at Buffalo, State University of New York), Joellen M. Schildkraut(Duke University Hospital), Keitaro Matsuo(Aichi Cancer Center), Argyrios Ziogas(University of Copenhagen), Anna H. Wu(University of Southern California), Lisa E. Paddock(Rutgers, The State University of New Jersey), Jennifer A. Doherty(Cancer Prevention Institute of California), Francesmary Modugno(University of Pittsburgh), Susan J. Jordan(The University of Queensland), Hoda Anton‐Culver(University of California, Irvine), Usha Menon(University of South Florida), Beth Y. Karlan(University of California, Los Angeles), Mika Mizuno(Aichi Cancer Center), Martin Köbel(University of Calgary), Brenda Diergaarde(University of Pittsburgh), Kevin H. Eng(Roswell Park Comprehensive Cancer Center), Mary Anne Rossing(Fred Hutch Cancer Center), Rebecca Sutphen(University of South Florida), Roberta B. Ness(The University of Texas Health Science Center at Houston), Celeste Leigh Pearce(University of Southern California), Robert P. Edwards(Magee-Womens Research Institute), Harvey A. Risch(University of New Haven)
Cited by 16
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
|Clinical Infectious Diseases|2008|4.9k
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k